Clin2
NCT06978738Possibly a fitNot yet recruiting

UCAR T-cell therapy for autoimmune diseases

Systemic Lupus ErythematosusAutoimmune Hemolytic AnemiaMyasthenia GravisSystemic SclerosisANCA-Associated VasculitisInflammatory MyopathyIgG4-RD

Part of Blood & lymphatic, Bones, joints & muscles, Brain & nervous system, Cancer, Heart & circulation, Immune system & allergy, Skin clinical trials.

This trial tests a new treatment using UCAR T-cells that target CD19 and BCMA proteins, for people with autoimmune diseases like lupus or arthritis that have come back or not responded to other treatments. It aims to see if this therapy can help control the disease.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 1
Enrollment
18 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • You must be 18 years or older.
  • You must have an autoimmune disease that has relapsed or is resistant to treatment, such as lupus or rheumatoid arthritis.
  • Your blood tests must show certain levels of white blood cells, red blood cells, and platelets.
  • Your liver and kidney function must be within acceptable limits.
  • You must be willing to use birth control if needed, and not be pregnant or breastfeeding.
  • You cannot have serious infections, heart problems, or certain cancers in the past 5 years.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07558850Recruiting
CAR-T Cell Therapy for Treatment-Resistant Autoimmune Diseases

This study tests a new type of immune cell therapy (CAR-T cells) designed to treat severe autoimmune diseases like rheumatoid arthritis, lupus, dermatomyositis, and scleroderma that haven't responded well to standard treatments. The therapy works by modifying your own immune cells to target and eliminate the B cells that are causing your autoimmune disease.

Nanjing, Jiangsu
NCT07246096Recruiting· Early Phase 1
CAR-T cell therapy for autoimmune diseases

This trial tests a new CAR-T cell treatment for people with certain autoimmune diseases that have not responded to standard therapies. The treatment uses your own immune cells modified to target and attack disease-causing cells.

Shanghai
NCT06691152Recruiting· Phase 1
CD19 UCAR T cells for severe lupus

This trial tests an experimental treatment called CD19 UCAR T cells for people with severe lupus that hasn't gotten better with standard medicines. It aims to see if these special immune cells can safely and effectively control the disease.

Hangzhou, Zhejiang
NCT06316076Recruiting· Phase 1
CD19 CAR-T cell therapy for autoimmune diseases

This trial tests a new type of immune cell therapy (CAR-T cells targeting CD19) for people with autoimmune diseases that haven't improved with standard treatments. The goal is to see if it is safe and can help control the disease.

Shanghai
NCT06941129Recruiting· Phase 1
CAR T-cell therapy for resistant autoimmune diseases

This trial tests a new type of immune therapy called CAR T-cells that target two markers on your B cells (CD19 and BCMA). It is for people with certain autoimmune diseases that have not improved or have come back after standard treatments. The goal is to see if this therapy can help control the disease.

Tianjin
NCT07212322Not yet recruiting
CD19 UCAR-T cells for autoimmune diseases

This trial tests a new cell therapy, CD19 UCAR-T cells, to see if it can help people with certain autoimmune diseases like lupus or scleroderma that haven't improved with standard treatments. It aims to reset the immune system by targeting and removing faulty B cells.

Tianjin, Tianjin Municipality

Hear when a new Systemic Lupus Erythematosus trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.